title: Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
authors.affiliation: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.|Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Reinhard
authors.affiliation: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.|Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Gebhardt
authors.affiliation: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Schmieder
authors.affiliation: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.|Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Umansky
authors.affiliation: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.|Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Utikal
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors; D010091:Oximes / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D011728:Pyridones / Q000009:adverse effects*; D011744:Pyrimidinones / Q000009:adverse effects*; D012008:Recurrence; D013653:Tattooing / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; D048493:Proto-Oncogene Proteins B-raf; D048369:MAP Kinase Kinase 1; C561627:dabrafenib